INTERVENTIONAL ONCOLOGY CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

19 Aug 2019

BOSTON SCIENTIFIC CLOSES ACQUISITION OF BTG PLC.

Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE:BTG) pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.

15 Aug 2019

BTG receives Health Canada Medical Device License for the ICEfx™ Cryoablation System

New technology provides physicians in Canada with a minimally invasive alternative to current tumour cryoablation procedures

BTG International Canada Inc. announced it has received a medical device license from Health Canada for the ICEfx™ Cryoablation System.

15 Aug 2019

Santé Canada accorde la licence d’instrument médical au système de cryoablation ICEfxMC de BTG

Grâce à cette nouvelle technologie, les médecins canadiens ont une solution de rechange très peu invasive aux interventions de cryoablation tumorale actuelles

BTG International Canada Inc., filiale de la société BTG plc (BTG à la Bourse de Londres) spécialiste mondial en produits médicaux, a annoncé l’approbation par Santé Canada de son système de cryoablation ICEfxMC.

23 Jul 2019

Recommendations for personalised HCC treatment with Y90 TheraSphere™ published by an international multidisciplinary group

Supported by comparative Dosisphere data, a phase II multicentric randomised dosimetry trial

BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere™ have been published by an international multidisciplinary working group¹. In addition, data from the Dosisphere phase II dosimetry trial supports MAA SPECT/CT based prospective personalised dosimetry².

25 Jun 2019

Radioembolization treatment for primary liver cancer and metastatic liver cancer now available in Argentina

Argentina now the second South American country to offer TheraSphere™ treatment for liver cancer patients

25 Jun 2019

Radioembolization treatment for primary liver cancer and metastatic liver cancer now available in Brazil

Brazil to be the first South American country to offer TheraSphere® treatment for liver cancer patients

5 Feb 2019

NHS England expands loco-regional treatment options for colorectal cancer patients with metastatic disease.

BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019, NHS England will routinely commission Selective Internal Radiation Therapy (SIRT) for colorectal cancer patients with liver-limited metastatic disease who are refractory or intolerant to chemotherapy.

21 Jan 2019

Australian Patient Treated With DC Bead LUMI™, the first commercially available Radiopaque Drug-Eluting Bead

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development of the market leading DC Bead®.

21 Dec 2018

BTG announces National Reimbursement for TheraSphere® in France 

An estimated 500 patients per year in France could be eligible for treatment with TheraSphere®

20 Sep 2018

BTG announces global launch of the ICEfx cryoablation system

September 20, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, today announced the global launch of the ICEfx Cryoablation System. ICEfx, an evolution of the existing Visual ICE system, offers predictable, reliable performance with seamless therapy delivery and exceptional ease of technical operation. This compact and powerful console is designed for interventional radiologists who want to offer their patients state-of-the-art, minimally invasive treatment options.

BTG Products